Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLVR NASDAQ:IMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVRClever Leaves$0.00$0.00▼$0.50$1K4212.865,336 shs3 shsIMTXImmatics$10.87-2.7%$10.48$4.62▼$12.41$1.50B1.31467,632 shs358,337 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVRClever Leaves0.00%0.00%+33.33%+300.00%+100.00%IMTXImmatics-2.69%-4.40%-1.18%+10.47%+138.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVRClever Leaves$0.00$0.00▼$0.50$1K4212.865,336 shs3 shsIMTXImmatics$10.87-2.7%$10.48$4.62▼$12.41$1.50B1.31467,632 shs358,337 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVRClever Leaves0.00%0.00%+33.33%+300.00%+100.00%IMTXImmatics-2.69%-4.40%-1.18%+10.47%+138.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLVRClever Leaves 0.00N/AN/AN/AIMTXImmatics 2.67Moderate Buy$19.0074.79% UpsideCurrent Analyst Ratings BreakdownLatest CLVR and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2026IMTXImmatics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/16/2026IMTXImmatics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.002/19/2026IMTXImmatics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00IMTXImmatics$54.60M26.69N/AN/A$3.98 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLVRClever Leaves-$17.90M-$12.36N/AN/AN/AN/AN/AN/AN/AIMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%N/ALatest CLVR and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLVRClever LeavesN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLVRClever LeavesN/AN/AN/AIMTXImmaticsN/A8.7811.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLVRClever Leaves6.92%IMTXImmatics64.41%Insider OwnershipCompanyInsider OwnershipCLVRClever Leaves8.20%IMTXImmatics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLVRClever Leaves5601.76 million1.61 millionNo DataIMTXImmatics260134.07 million129.65 millionOptionableCLVR and IMTX HeadlinesRecent News About These CompaniesAnalysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter ResultsMay 15 at 11:06 PM | finance.yahoo.comImmatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 13 at 4:32 AM | americanbankingnews.comImmatics (IMTX) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2026 | zacks.comImmatics Announces First Quarter 2026 Financial Results and Business UpdateMay 12, 2026 | globenewswire.comImmatics (IMTX) Expected to Announce Earnings on TuesdayMay 10, 2026 | americanbankingnews.comAll You Need to Know About Immatics (IMTX) Rating Upgrade to BuyMay 6, 2026 | zacks.comImmatics (IMTX) to Release Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comImmatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street ZenMay 2, 2026 | marketbeat.comTD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendationApril 29, 2026 | msn.comImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in ...April 19, 2026 | caledonianrecord.comCPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaApril 18, 2026 | markets.businessinsider.comImmatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 18, 2026 | marketbeat.comImmatics Phase 3 Progress Sharpens View On Anzu Cel Launch UpsideMarch 15, 2026 | finance.yahoo.comImmatics NV (IMTX) seeing strong enrollment in a key phase 3 trial of drug candidateMarch 13, 2026 | msn.comImmatics: Buying The Anzu-Cel Floor, Playing The Moderna MoonshotMarch 9, 2026 | seekingalpha.comImmatics Announces Full Year 2025 Financial Results and Business UpdateMarch 5, 2026 | markets.businessinsider.comImmatics: Q4 Earnings SnapshotMarch 5, 2026 | wtop.comWInstitutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)January 15, 2026 | finance.yahoo.comBank of America Securities Reaffirms Their Buy Rating on Immatics (IMTX)January 12, 2026 | theglobeandmail.comImmatics price target raised to $17 from $14 at BofAJanuary 6, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLVR and IMTX Company DescriptionsClever Leaves NASDAQ:CLVRClever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Immatics NASDAQ:IMTX$10.87 -0.30 (-2.69%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$10.67 -0.20 (-1.88%) As of 05/15/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
